Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable do...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Paul Tamburini, Dennis Vestergaard Pedersen, Denise Devore, Josh Cone, Rekha Patel, Todd Hunter, Fang Sun, Gregers Rom Andersen, Jeffrey Hunter
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2024-12-01
Serija:	mAbs
Teme:	Bispecific VHH antibody complement alternative pathway complement inhibition preclinical study properdin tarperprumig
Online dostop:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2415060
Oznake:	Označite Brez oznak, prvi označite!